Reports Q1 revenue $1.34B, consensus $1.33B. “Our fiscal year 2026 is off to a strong start, with first-quarter performance reflecting continued progress toward our mission of helping people sleep better, breathe better and live longer and healthier, with care provided in their own home,” said Resmed’s (RMD) Chairman and CEO, Mick Farrell.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- RMD Earnings this Week: How Will it Perform?
- ResMed’s Nyx3 Study: A New Frontier in Sleep Technology
- ResMed’s ASV Therapy Study: A New Hope for Insomnia?
- ResMed’s New Study: Pioneering Non-Invasive Sleep Apnea Diagnosis
- ResMed’s New Algorithm Study: A Potential Game-Changer for Sleep Apnea Treatment